Applications of N-Boc-Beta-Phenyl-L-Phenylalaninol in Industrial Manufacturing

N-Boc-Beta-Phenyl-L-Phenylalaninol serves as a key intermediate in several high-value synthesis routes. Leveraging our in-depth production experience, we support leading manufacturers by supplying this critical raw material for tightly regulated pharmaceutical, peptide, and specialty chemical applications. With a focus on process consistency and regulatory alignment, we ensure our material integrates directly into industrial-scale projects with clear performance and compliance benefits.

1. Chiral Building Block for Peptide API Synthesis

Major peptide API manufacturers make use of N-Boc-Beta-Phenyl-L-Phenylalaninol as a stereochemically pure building block for synthesizing custom peptide chains, especially where β-amino acid derivatives impart specific bioactivity. The controlled introduction of this intermediate enhances β-peptide stability and target interaction, supporting the development of next-generation peptide drug substances.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia 10th Edition (monograph specifications for chiral peptide constituents)
• US FDA cGMP 21 CFR Part 210/211
• EDQM CEP requirements for intermediates

Typical usage ratio

• Used at 1-2 molar equivalents per targeted residue in peptide elongation reactions; ratio adjustment based on sequence length and targeted β-amino acid incorporation

Downstream process integration

• Introduced following standard Fmoc or Boc solid-phase peptide synthesis (SPPS) cycles; protected amine functionality allows selective chain extension at the desired position; final deprotection after chain assembly

Final product types

• Pharmaceutical-grade peptide active ingredients (APIs)
• β-amino acid-based therapeutic peptides for metabolic disease and oncology research

2. Intermediate for Chiral Active Pharmaceutical Ingredients (APIs)

R&D and commercial API facilities utilize this compound during the construction of chiral side chains in drugs targeting neurological or cardiovascular indications. Its structure enables introduction of β-phenyl moieties while maintaining the required stereochemistry defined in drug master files.

Industry compliance standards

• US Pharmacopeia (USP) API monograph section for chiral intermediates
• ICH Q3A/B Impurities Guidelines (for controlling isomeric and process impurities)
• Japanese Pharmacopoeia 18th Edition (applicable for APIs with chiral centers)
• FDA DMF (Drug Master File) referencing for intermediate sourcing

Typical usage ratio

• Employed in 0.8-1.5 equivalents for key coupling steps; ratio tailoring depends on yield optimization and minimization of side-product formation

Downstream process integration

• Functions as the chiral auxiliary or primary subunit in multi-step synthesis; typically used before reductive amination, chiral resolution, or final API deprotection

Final product types

• Chiral pharmaceutical APIs for CNS disorders and cardiovascular drugs
• Finished dosage forms (tablets, injectables) based on β-phenyl-containing active substances

3. Precursor for Asymmetric Organocatalysis

Custom fine chemical producers incorporate N-Boc-Beta-Phenyl-L-Phenylalaninol as an enantiopure scaffold for tailoring organocatalysts. These catalysts accelerate stereoselective transformations required in green synthesis routes for advanced materials and flavor ingredients.

Industry compliance standards

• ISO 9001:2015 certified quality management system in catalyst manufacturing
• REACH registration for commercial-scale production and import in the EU
• Food Chemical Codex compliance for catalysts used in natural flavor preparations (where applicable)
• Responsible Care Certification for safe chemical handling

Typical usage ratio

• Formulated at 5-15 wt% for immobilized or free-organocatalyst synthesis processes; specific loading depends on targeted substrate turnover and catalyst recyclability

Downstream process integration

• Combined with other chiral reagents to generate bifunctional organocatalyst frameworks; enters reaction at the scaffold assembly or functionalization stage

Final product types

• Batch and continuous-use asymmetric organocatalysts
• Chiral auxiliaries for production of optically active flavor and fragrance intermediates

4. Intermediate for Specialty Chemical Synthesis: Chiral Ligands and Auxiliaries

Industrial laboratories and advanced synthesis operations apply this molecule as a starting point for synthesizing chiral ligands and auxiliaries used in stereoselective metal-catalyzed transformations. Its protected amine facilitates tailored ligand design, enhancing selectivity and yield across multiple catalytic systems.

Industry compliance standards

• OECD Good Laboratory Practice (GLP) for specialty chemical R&D
• ISO 17025 accreditation for analytical traceability
• REACH chemical safety compliance for supply chain transparency
• Internal corporate specifications for moisture, residue, and heavy metal content in ligand precursors

Typical usage ratio

• Introduced at 1 equivalent per ligand synthesis; ratio adjusted to the number of coordination sites required in targeted complex structures

Downstream process integration

• Added in the ligand precursor assembly, with subsequent Boc deprotection and further functionalization to access chelating or mono/dentate ligand forms suitable for transition metal catalysis

Final product types

• Chiral ligands for use in enantioselective hydrogenation and cross-coupling catalysts
• Auxiliaries for asymmetric synthesis of pharmaceutical or agrochemical intermediates